Juul has filed a complaint with the U.S. International Trade Commission demanding 18 companies stop selling e-cigarettes and saying their products infringe on its patents. Days earlier, the FDA seized documents during a surprise inspection of Juul’s headquarters. (CNBC)

BIO sent a letter to its members on Wednesday demanding they improve executive gender diversity. Only 10% of the biotech industry’s board seats and 25% of C-suite positions are occupied by women. The letter also condemned BIO conference after-parties that are inconsistent with its code of conduct, four months after the Party at BIO Not Associated with BIO, which featured topless dancers, was widely criticized. (Endpoints)

Johnson & Johnson made a deal with Arrowhead Pharmaceuticals that could be worth more than $3.7 billion to develop and market its gene-silencing Hepatitis B drug. J&J will receive a worldwide license for the drug and can collaborate on three RNA interference drugs, as well. (Reuters)

Memorial Sloan Kettering’s CEO has stepped down from Merck’s board of directors. Craig Thompson’s decision came after MSK chief medical officer Dr. José Baselga resigned for not disclosing payments from pharmaceutical and healthcare companies. Merck’s board will shrink to 12 members. (Bloomberg)

Roche’s new flu drug was found to not be significantly better at reducing symptoms than generic Tamiflu. According to Phase III Capstone-2 trial data, Roche’s baloxavir improved symptoms in 73.2 hours in comparison to Tamiflu, which took 81 hours. (Endpoints)